Ginkgo Bioworks to become public today

The biotech is to go public at a valuation of $15 billion. Ginkgo manufactures bacteria with industrial applications and leads the synthetic biology market.

Ginkgo Bioworks is set to go public by merging with Soaring Eagle Acquisition Corp., a SPAC.

The shares acquired by investors at the pre-IPO stage will be converted into shares of the public company (DNA ticker) in a certain ratio. We are awaiting information on the conversion rate from Ginkgo Bioworks. This means that for a while Ginkgo stock price in your personal account will not match the DNA stock price. 

In October 2020, when we offered investments in Ginkgo Bioworks pre-IPO stocks, the stock was worth $138.6 at a total valuation of $4.5 billion. Today, the company will go public with a valuation of $15 billion.

Stay tuned for any updates!